Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders.
Menghini, M
Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders. [electronic resource] - Klinische Monatsblatter fur Augenheilkunde Apr 2010 - 244-8 p. digital
Publication Type: Journal Article
1439-3999
10.1055/s-0029-1245203 doi
Aged
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Female
Humans
Macular Degeneration--drug therapy
Male
Prevalence
Prognosis
Ranibizumab
Retrospective Studies
Risk Assessment
Risk Factors
Sex Distribution
Switzerland--epidemiology
Treatment Outcome
Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders. [electronic resource] - Klinische Monatsblatter fur Augenheilkunde Apr 2010 - 244-8 p. digital
Publication Type: Journal Article
1439-3999
10.1055/s-0029-1245203 doi
Aged
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Female
Humans
Macular Degeneration--drug therapy
Male
Prevalence
Prognosis
Ranibizumab
Retrospective Studies
Risk Assessment
Risk Factors
Sex Distribution
Switzerland--epidemiology
Treatment Outcome